ACM
PBYI icon

Asymmetry Capital Management’s Puma Biotechnology PBYI Stock Holding History

Asymmetry Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,057
Closed -$1.23M – 40
2018
Q1 		$1.23M Buy
18,057
+10,686
+145% +$800K 1.54% 23
2017
Q4 		$729K Buy
+7,371
New +$825K 0.99% 26
2017
Q2 		– Sell
-42,524
Closed -$1.58M – 34
2017
Q1 		$1.58M Buy
+42,524
New +$1.55M 2.21% 17

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Asymmetry Capital Management's PBYI Position: Q2 2018 in Review

Asymmetry Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 18,057 shares — an estimated $1.23M sold.

Asymmetry Capital Management first reported a position in PBYI in Q1 2017 and held it in 3 quarters. The position peaked at $1.58M in Q1 2017. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

  • Asymmetry Capital Management reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 18,057 Puma Biotechnology shares in Q2 2018, an estimated $1.23M.
  • Asymmetry Capital Management first reported a position in Puma Biotechnology in Q1 2017 and held it in 3 quarters.
  • Asymmetry Capital Management's Puma Biotechnology position peaked at $1.58M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Asymmetry Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.